The abstract is read at the publisher; the summary is JClub's.
Brain-derived mitovesicles are enriched in Alzheimer’s disease patients and 5×FAD mice, and their Ggt1 cargo drives AD-like behavioral and pathological changes in wild-type and 5×FAD mice.
- Why it matters: EVs can spread pathogenic factors in AD, but the specific role of mitovesicles and their disease-relevant cargo has been unclear.
- What they did: The study quantified mtV release in AD patient brain tissue and 5×FAD mice, administered 5×FAD brain-derived mtVs to wild-type mice, and used proteomics to identify Ggt1 as highly enriched; mtV release was also linked to mitochondrial respiratory metabolism.
- The result: Blocking mtV release and inhibiting Ggt1 expression and activity significantly mitigated AD-like phenotypes in 5×FAD mice and delayed ADmtV-induced disease progression, supporting mtVs and Ggt1 as therapeutic targets.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.